{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T02:36:11Z","timestamp":1761964571961},"reference-count":26,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2014,6,30]],"date-time":"2014-06-30T00:00:00Z","timestamp":1404086400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2014,10]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>The estimation of survival of myelodysplastic syndromes (<jats:styled-content style=\"fixed-case\">MDS<\/jats:styled-content>) and risk of progression into acute myeloid leukaemia is challenging due to the heterogeneous clinical course. The most widely used prognostic scoring system (International Prognostic Scoring System [<jats:styled-content style=\"fixed-case\">IPSS<\/jats:styled-content>]) was recently revised (<jats:styled-content style=\"fixed-case\">IPSS<\/jats:styled-content>\u2010R). The aim of this study was to investigate the prognostic relevance of flow cytometry (<jats:styled-content style=\"fixed-case\">FC<\/jats:styled-content>) in the context of the<jats:styled-content style=\"fixed-case\">IPSS<\/jats:styled-content>\u2010R. Bone marrow aspirates were analysed by<jats:styled-content style=\"fixed-case\">FC<\/jats:styled-content>in 159 patients with<jats:styled-content style=\"fixed-case\">MDS<\/jats:styled-content>. A flow score was calculated by applying the flow cytometric scoring system (<jats:styled-content style=\"fixed-case\">FCSS<\/jats:styled-content>). Patients were assigned to<jats:styled-content style=\"fixed-case\">IPSS<\/jats:styled-content>and<jats:styled-content style=\"fixed-case\">IPSS<\/jats:styled-content>\u2010R risk groups. The<jats:styled-content style=\"fixed-case\">FCSS<\/jats:styled-content>correlated with the World Health Organization classification,<jats:styled-content style=\"fixed-case\">IPSS<\/jats:styled-content>and<jats:styled-content style=\"fixed-case\">IPSS<\/jats:styled-content>\u2010R risk groups. Mild flow cytometric abnormalities were associated with significantly better overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>) and lower risk of disease evolution. The presence of aberrant myeloid progenitors was associated with transfusion dependency and disease progression. Most importantly, the<jats:styled-content style=\"fixed-case\">FCSS<\/jats:styled-content>identified prognostic subgroups within the<jats:styled-content style=\"fixed-case\">IPSS<\/jats:styled-content>\u2010R cytogenetic good risk and low risk group. Flow cytometric analysis in patients with<jats:styled-content style=\"fixed-case\">MDS<\/jats:styled-content>provides additional prognostic information and is complementary to the<jats:styled-content style=\"fixed-case\">IPSS<\/jats:styled-content>\u2010R. The addition of a flow cytometric score next to the clinical parameters within the<jats:styled-content style=\"fixed-case\">IPSS<\/jats:styled-content>\u2010R is a further refinement of prognostication of patients with<jats:styled-content style=\"fixed-case\">MDS<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/bjh.12994","type":"journal-article","created":{"date-parts":[[2014,7,1]],"date-time":"2014-07-01T00:51:52Z","timestamp":1404175912000},"page":"100-109","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["High flow cytometric scores identify adverse prognostic subgroups within the revised international prognostic scoring system for myelodysplastic syndromes"],"prefix":"10.1111","volume":"167","author":[{"given":"Canan","family":"Alhan","sequence":"first","affiliation":[{"name":"Department of Haematology Cancer Centre Amsterdam VU University Medical Centre Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresia M.","family":"Westers","sequence":"additional","affiliation":[{"name":"Department of Haematology Cancer Centre Amsterdam VU University Medical Centre Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eline M. P.","family":"Cremers","sequence":"additional","affiliation":[{"name":"Department of Haematology Cancer Centre Amsterdam VU University Medical Centre Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Cali","sequence":"additional","affiliation":[{"name":"Department of Haematology Cancer Centre Amsterdam VU University Medical Centre Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Birgit I.","family":"Witte","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Biostatistics VU University Medical Centre Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gert J.","family":"Ossenkoppele","sequence":"additional","affiliation":[{"name":"Department of Haematology Cancer Centre Amsterdam VU University Medical Centre Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arjan A.","family":"van de Loosdrecht","sequence":"additional","affiliation":[{"name":"Department of Haematology Cancer Centre Amsterdam VU University Medical Centre Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,6,30]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.7379"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.1982.tb02771.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-10-4149"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2011.02.016"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.b.20582"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V89.6.2079"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-03-420489"},{"key":"e_1_2_8_9_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Jaffe E.S.","year":"2001"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25353"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-07-098764"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2009.005801"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2012.718341"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.01.7038"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403680"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.5696"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.044602"},{"key":"e_1_2_8_18_1","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/cyto.b.20513","article-title":"Bone marrow cells from myelodysplastic syndromes show altered immunophenotypic profiles that may contribute to the diagnosis and prognostic stratification of the disease: a pilot study on a series of 56 patients","volume":"78","author":"Matarraz S.","year":"2010","journal-title":"Cytometry Part B Clinical Cytometry"},{"key":"e_1_2_8_19_1","volume-title":"ISCN: An International System for Human Cytogenetic Nomenclature 1995","author":"Mitelman F.","year":"1995"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.28.3978"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-05-153700"},{"key":"e_1_2_8_22_1","volume-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","author":"Swerdlow S.H.","year":"2008"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2009.02.021"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.leukres.2006.11.009"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-09-2768"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-08-239749"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.30"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.12994","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.12994","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,28]],"date-time":"2024-05-28T09:53:20Z","timestamp":1716890000000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.12994"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,6,30]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,10]]}},"alternative-id":["10.1111\/bjh.12994"],"URL":"https:\/\/doi.org\/10.1111\/bjh.12994","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,6,30]]},"assertion":[{"value":"2014-02-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-04-21","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-06-30","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}